- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00109733
Cool.Click™ Adolescent Transition Study: Study of Saizen® in Subjects With Childhood-onset Growth Hormone Deficiency
A Phase IIIb, Prospective, Multicenter, Randomized, Open-label Study to Determine the Safety and Efficacy of Two Different Dosing Regimens of Saizen® (Recombinant Human Growth Hormone (r-hGH), Using Cool.Click™ in Subjects With Childhood-onset Growth Hormone Deficiency During the Adolescent Transition Phase (CATS)
Study Overview
Status
Intervention / Treatment
Detailed Description
This is a phase IIIb, prospective, multicenter, randomised, open label study to determine the safety and efficacy of two different dose regimens of r-hGH with a dose escalation scheme. Screening assessments must be completed 30 days prior to SD1 (Study Day 1). Eligible subjects ages 13 to 25 years will be randomised in equal allocation in a 1:1 ratio to one of two treatment groups (30 subjects/group). Daily subcutaneous injections will be self-administered or received from a designated individual using cool.click™, the needle-free growth hormone (GH) delivery device. The study consists of three periods: screening (up to 30 days prior to Study Day 1), active treatment (up to 24 weeks), and follow-up (4 week safety evaluation after the last dose of study medication).
Each subject will be required to complete a daily treatment diary to assess dosing compliance, adverse events, and concomitant medications. Each subject will receive one treatment diary at SD1, weeks 8, 12, and 24. Subjects will be required to record daily diary entries that will capture dosing compliance, adverse events, and concomitant medications. Depending upon treatment allocation and subject tolerability, dose titration will be increased as follows:
- Group A: 0.005 mg/kg/day for 30 days then increasing, with the Investigator's approval, to 0.010 mg/kg/day from day 31 to week 24.
- Group B: 0.010 mg/kg/day for 14 days with the opportunity to dose escalate, with the Investigator's approval, on day 15 to 0.02 mg/kg/day and day 29 to 0.03 mg/kg/day.
Scheduled study visits include screening, baseline, and weeks 8, 12, and 24. Dosage adjustments will be based on subject tolerability and telephone assessments from study drug initiation through week 6. Trunk fat will be measured at SD1, weeks 12 and 24 (or early termination visit). Routine clinical laboratory assessments (hematology, blood chemistries, and urinalysis) will be performed pre-treatment (-30 to -1 SD1) and post-treatment on week 24 (or early termination visit). Special laboratory assessments include the central analysis of lipid panel, fasting insulin, fasting glucose, insulin-like growth factor I (IGF-I), insulin-like growth factor binding protein 3 (IGFBP-3), free thyroxine (T4) , total T4, C-reactive protein (CRP). Physical exams will be performed at screening, weeks 12 and 24. Safety evaluations will occur during scheduled study visits, through telephone assessments, and by the review of adverse events and concomitant events on the subject treatment diary.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
California
-
Orange, California, United States, 92868
- Children's Hospital of Orange County
-
-
Florida
-
Jacksonville, Florida, United States, 32226
- Nemours Children's Clinic
-
Orlando, Florida, United States, 32806
- Nemours Children's Clinic
-
Tallahassee, Florida, United States, 32308
- Pediatric Endocrinology Children's Clinic
-
-
Georgia
-
Atlanta, Georgia, United States, 30342
- Pediatric Endocrine Associates
-
-
New York
-
Buffalo, New York, United States, 14222
- Women's and Children's Hospital of Buffalo
-
New York, New York, United States, 10032
- Columbia University
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- Children's Hospital of Pittsburgh
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53226
- Children's Hospital of Wisconsin
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
The day of entry or Study Day 1 is defined as the first day of study treatment. To be eligible for inclusion into this study, the subjects must fulfill all of the following criteria within 30 days prior to Study Day 1.
- Male or female from 13 to 25 years of age, inclusive
- Diagnosis of childhood onset growth hormone deficiency (GHD) and prior completed growth hormone (GH) treatment as evidenced by bone age greater than 14 years for girls and 16 years for boys or no height increase > 0.5 cm in the 6 months prior to Screen.
- Have documented GH deficiency (acquired or idiopathic), established by a standard provocative test, such as insulin (<5 ng/mL) or growth hormone releasing hormone plus arginine (<9 ng/mL) at least 30 days after GH has been discontinued. If a subject is hypopituitary with two or more pituitary disorders and has a low IGF-1, the stimulation test does not need to be performed to confirm GHD.
- If hypopituitary, must have been on adequate replacement therapy (if required) of glucocorticosteroids, thyroid and sex hormones (hormone levels on replacement being in normal/mildly elevated range) for at least 6 months prior to Screen.
- Be willing and able to comply with the protocol for the duration of the study.
- Have given written informed consent before any study-related procedure not part of the subject's normal medical care, with the understanding that the subject may withdraw consent at any time without prejudice to future medical care.
- Female subjects of childbearing potential must use a hormonal contraceptive, intra-uterine device, diaphragm with spermicide or condom with spermicide for the duration of the study. Confirmation that a female patient is not pregnant must be established by a negative human chorionic gonadotrophin (hCG) pregnancy test (urine or serum) within 7 days of study enrolment (SD1).
Exclusion Criteria:
To be eligible for inclusion in this study the subjects must not meet any of the following criteria:
- Known allergy or hypersensitivity to growth hormone or diluent.
- Previous treatment with GH within six months prior to Screen.
- Severe illness during the previous six months.
- Active malignancy (except non-melanomatous skin malignancies).
- Diabetes mellitus (type I or II).
- Seropositivity for human immunodeficiency virus (HIV), Hepatitis B surface antigen (HbsAg) and/or Hepatitis C Virus (HCV) serology.
- Pregnancy or lactation.
- History of drug and/or alcohol abuse or use of drugs for non-therapeutic purposes.
- Any medical condition that, in the opinion of the Investigator, would jeopardize the patient's safety following exposure to study drug.
- Clinically significant abnormal hematology, chemistry or urinalysis results at screening in the judgment of the Investigator.
- Have taken another investigational drug or had any experimental procedure in the six months preceding study entry.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Standard dose group
0.005 mg/kg/day recombinant human growth hormone (r-hGH) for 30 days then increasing, with the Investigator's approval, to 0.010 mg/kg/day from Day 31 to Week 24.
|
0.005 mg/kg/day for 30 days then increasing, with the Investigator's approval, to 0.010 mg/kg/day from Day 31 to Week 24.
Other Names:
0.010 mg/kg/day for 14 days with the opportunity to dose escalate, with the Investigator's approval, on Day 15 to 0.02 mg/kg/day and Day 29 to 0.03 mg/kg/day.
Other Names:
|
Experimental: High dose group
0.010 mg/kg/day recombinant human growth hormone for 14 days with the opportunity to dose escalate, with the Investigator's approval, on Day 15 to 0.02 mg/kg/day and Day 29 to 0.03 mg/kg/day.
|
0.005 mg/kg/day for 30 days then increasing, with the Investigator's approval, to 0.010 mg/kg/day from Day 31 to Week 24.
Other Names:
0.010 mg/kg/day for 14 days with the opportunity to dose escalate, with the Investigator's approval, on Day 15 to 0.02 mg/kg/day and Day 29 to 0.03 mg/kg/day.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Percent Change From Baseline to Week 24 in Trunk Fat
Time Frame: Baseline to Week 24
|
Baseline to Week 24
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Percent Change From Baseline to Week 24 in Lean Body Mass
Time Frame: Baseline to Week 24
|
Baseline to Week 24
|
Percent Change From Baseline to Week 24 in Total Body Fat
Time Frame: Baseline to Week 24
|
Baseline to Week 24
|
Percent Change From Baseline to Week 24 in Limb Fat
Time Frame: Baseline to Week 24
|
Baseline to Week 24
|
Percent Change From Baseline to Week 24 in Trunk to Limb Fat Ratio
Time Frame: Baseline to Week 24
|
Baseline to Week 24
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Sanja Dragnic, MD, EMD Serono
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Genetic Diseases, Inborn
- Musculoskeletal Diseases
- Hypothalamic Diseases
- Bone Diseases
- Bone Diseases, Endocrine
- Pituitary Diseases
- Bone Diseases, Developmental
- Hypopituitarism
- Dwarfism, Pituitary
- Endocrine System Diseases
- Dwarfism
- Physiological Effects of Drugs
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Hormones
Other Study ID Numbers
- 25253
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pituitary Dwarfism
-
Nemours Children's ClinicNovo Nordisk A/S; Children's Hospital Los AngelesCompletedPituitary Dwarfism | Idiopathic Short StatureUnited States
-
Novo Nordisk A/SCompletedHypopituitarism | Growth Hormone Disorder | Pituitary DwarfismUnited States
-
Novo Nordisk A/SCompletedGrowth Hormone Disorder | Pituitary DwarfismUnited States
-
Merck KGaA, Darmstadt, GermanyMerck Serono Co., Ltd., ChinaCompleted
-
The Cleveland ClinicMassachusetts General Hospital; Oregon Health and Science University; Allegheny...CompletedAdult Growth Hormone Deficiency | Hypothalamic-pituitary DisordersUnited States
-
Visen Pharmaceuticals (Shanghai) Co., Ltd.Ascendis Pharma A/SUnknownEndocrine System Diseases | Pituitary Diseases | Growth Hormone Deficiency | Hormones | Pituitary Disease, AnteriorChina
-
PfizerCompletedDwarfism, Growth Hormone Deficiency
-
Massachusetts General HospitalCompletedAcromegaly | Growth Hormone Deficiency | Pituitary DiseaseUnited States
-
AEterna ZentarisCompletedGrowth Hormone Deficiency With Pituitary AnomaliesUnited Kingdom, United States, France, Poland, Spain, Austria, Germany, Italy, Serbia
-
LG Life SciencesBioPartners GmbHCompletedAdult Growth Hormone Deficiency | Pituitary DisordersUnited States
Clinical Trials on recombinant human growth hormone
-
Ache Laboratorios Farmaceuticos S.A.Unknown
-
Columbia UniversityTercicaTerminatedGrowth Hormone DeficiencyUnited States
-
CinnagenCompleted
-
Massachusetts General HospitalGenentech, Inc.CompletedAnorexia Nervosa | Osteoporosis | Osteopenia | Eating DisordersUnited States
-
Versartis Inc.Completed
-
Postgraduate Institute of Medical Education and...UnknownChronic Myelogenous Leukemia | Short StatureIndia
-
University of Maryland, BaltimoreChildren's Hospital of PhiladelphiaWithdrawnOsteoporosis Pseudoglioma SyndromeUnited States
-
University Hospital TuebingenCompleted
-
Weill Medical College of Cornell UniversityGenentech, Inc.TerminatedChronic Kidney DiseaseUnited States
-
GeneScience Pharmaceuticals Co., Ltd.Tongji Hospital; Shengjing Hospital; Shandong Provincial Hospital; Children's Hospital... and other collaboratorsRecruiting